Pioneering AI-driven predictive oncology
BeLiver is born from cutting-edge French research, with a clear ambition : advancing cancer care. We develop AI-powered tools designed to turn complex biological data into clear, actionable insights, supporting personalized treatment decisions that aim to improve patient outcomes.
We begin with liver cancer, but our vision extends far beyond.
Rooted in science, driven by unmet medical need
BeLiver emerged from the pioneering work of Bordeaux University Hospital (CHU) and the INSERM/CNRS research unit BRIC (Bordeaux Institute Of Oncology).
Our founders identified a critical gap : patients with the same diagnosis often respond very differently to standard treatments. The reason? A lack of tools to truly capture the biological complexity of each tumor.
This challenge became our mission : to develop a new generation of decision-support tools that bring rationality and clarity to therapeutic choices.
By combining advanced proteomics with AI, we are developing personalized treatment predictions designed to help each patient receive the most suitable therapy from the start.
Discover our services
Team
Madeleine Moscatelli, PhD
CEO & Co-Funder
Former start-up funder
Business
Frédéric Saltel, PhD
CSO & Co-Funder
Director of the Bordeaux Oncology Institute
Clinic
Anne-Aurélie Raymond, PhD
CTO & Co-Funder
Head of the OncoProt platform & KOL in proteomics
Hardware
Hadrien Mary, PhD
Deputy CTO & Partner
AI for Biology Expert & Ex-Recursion Pharmaceuticals
AI & Modeling
Tatiana Cohen de Lara
Chief of Staff
Strategic Partnerships
Advisory Board
Perspectives from leaders in the field
« This technology will be the first step towards truly personalized medicine in digestive oncology. »
Pr. Jean Frédéric Blanc
KOL in digestive oncology
BeLiver Board
Interested in partnering with us?
Clinicians, researchers, pharma companies: let's shape the future of precision oncology together.
Connect with us